分子药剂学与新释药系统北京市重点实验室，于2015年通过北京市科委认定，正式建立。建设期中承担并顺利完成北京市基地建设和人才培养专项任务，于2018年顺利通过北京市科委的验收。

实验室依托北京大学药剂学科，由张强教授担任实验室主任、吕万良教授和戴志飞教授担任实验室副主任。实验室现有在岗、全职教学科研人员26人，硕士/博士研究生与博士后120人。实验室科研用房面积2000平米以上，有科研用仪器设备80多台套。

 

研究领域及方向

主要研究方向：在分子药剂学方面，主要针对药剂学领域前沿和重大科学问题，开展应用基础研究；在新释药系统方面，主要针对药剂学领域共性关键技术，开展应用转化研究。

主要研究领域：1.新型抗肿瘤靶向释药系统及作用机制，包括在分子水平上设计构建新型抗肿瘤靶向释药系统，揭示其用于肿瘤诊断、肿瘤治疗、肿瘤耐药、肿瘤转移等的可行性，阐明其分子机理等；2.新型载体释药系统及作用机制，包括新型载体释药系统载体的设计组装，揭示其释药、跨膜转运、药效作用等的规律性，阐明其生物安全性和作用机理等；3.新释药系统的开发，包括相关释药技术研究和上述二类释药系统的临床前研究，与北京市相关制药企业合作，转化相关释药系统新产品。

 

机构科研基础

1.综合研究实力较强：实验室先后获得973、863、自然科学基金重大和重点项目、重大专项单元平台等国家级重大重点项目的支持；先后获得过国家科技进步二等奖、教育部自然科学一等奖、中国药学会科学技术奖一等奖、吴阶平-保罗杨森奖一等奖等；在自然子刊等学术杂志发表系列高影响学术论文；实现一系列高端药物制剂的技术转化，产生了非常好的社会经济效益；

2.具有国内一流药学院校和一流综合性大学的学科优势：我们是药学一级学科博士授权单位和全国一级重点学科的组成部分，北京大学药学院为传统五院校之一，所在的北京大学是211和985建设高校，也是国家优先发展的两所重点大学之一；所在的北京大学药学院、医学部和校本部具有一流的试验研究平台和条件；

3.具有国内一流的研究团队：我们是国内药剂学领域第一个也是目前唯一的一个教育部创新团队；实验室主任张强教授长期担任中国药学会药剂专业委员会主任委员，是世界控释协会（CRS）中国分会首任主席；团队成员包括973首席科学家、杰出青年、长江学者、青年千人、优青和北京市杰出青年等，2人成为Elsevier中国高被引作者。

    

近年来的重要科研成果及贡献

近年来，针对分子药剂学领域的重大科学问题，实验室创新构建了回避溶酶体降解的转运途径选择性纳米载体、精准程序响应癌细胞内外分子信号的智能纳米诊疗系统、共价有机纳米聚合物共递送系统等，实现了高效和特异性药物递送；率先用蛋白组学技术揭示分子微环境调控纳米载体细胞转运的新分子机制，首次发现配体各向异性调控纳米-生物互作等，从分子水平上阐明了系列关键科学问题。在新释药系统方面，近年来也实现了一系列高端药物制剂的技术转化。在自然子刊等学术杂志发表系列高影响学术论文；与国内外大型药企业开展了系列合作；组织参与多项大型国内外学术活动，先后获得国家科技进步奖、教育部自然科学奖和北京市科学技术奖。

 

机构负责人：张强

联系人：张华

邮箱：zhangpharm@bjmu.edu.cn

电话：010-82805724

地址：北京市海淀区学院路38号

 

 

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems

 

The Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems was officially established in 2015, approved by the Beijing Science and Technology Commission. During the three-year construction period, it undertook and successfully completed the special task of Beijing Base Construction and Talent Cultivation. In 2018, the laboratory passed the acceptance inspection of Beijing Science and Technology Commission with excellent achievements.

The laboratory is based on the Department of Pharmaceutics of Peking University, with Professor Qiang Zhang as the director, and Professor Wanliang Lyu and Professor Zhifei Dai as the vice directors. The laboratory currently holds 26 full-time teaching and research faculty members, 120 master/doctorate students and post-doctoral researchers. The scientific research building belonging to our laboratory covers an area of ？？more than 2,000 square meters, and there are more than 80 sets of equipment.

 

Research Directions and Areas

Main research directions: With respect to Molecular Pharmaceutics, the laboratory mainly focuses on the frontier and major scientific issues in the field of Pharmaceutics, and conducts basic research for possible application; in terms of new drug delivery systems, the laboratory primarily pays attention to common key technologies in the field of Pharmaceutics and conducts applied transformational research.

Main research areas: 1. New anti-tumor targeting drug delivery systems and their mechanisms of action, including the designing and constructing novel anti-cancer targeting drug delivery platforms at the molecular level, revealing the feasibility of their utilization in tumor diagnosis, tumor treatment, overcoming tumor drug resistance, and reducing tumor metastasis, and elucidating their molecular mechanism, etc.; 2. Drug delivery systems based on new-type carriers and their mechanisms of action, including the designing and assembling new carriers for drug delivery, revealing the regularity of drug release, transmembrane transport, therapeutic efficacy, etc., and clarifying their biological safety and mechanisms of action, etc.; 3. Development of new drug release systems, including research on related drug delivery technologies and pre-clinical study on the aforesaid two kinds of drug delivery systems, and cooperation with relevant pharmaceutical companies in Beijing to transform related drug delivery systems into novel marketing products.

 

Institutional Strength  

1. Strong comprehensive research strength: The laboratory has successively won the support from “973”, “863”, the Major and Key Project of the Natural Science Foundation, the Major Special Unit Platform and other national-level significant and essential projects; successively won the Second Prize of the National Science and Technology Progress Award, the First Prize of Natural Science of the Ministry of Education, the First Prize of Science and Technology Award of Chinese Pharmaceutical Association, the First Prize of Wu Jieping-Paul Janssen Award, etc.; published a series of high-impact academic papers in academic journals such as the journals of Nature Press; realized the technological transformation of a variety of high-end pharmaceutical preparations, and achieved excellent social and economic benefits;
2. Possessing the advantages of domestic first-class Pharmacy college and top-tier comprehensive university: Our laboratory constitutes to the institution conferring the first-class doctorate degree in Pharmacy and owning the first-class state key discipline. Noted, the School of Pharmaceutical Sciences of Peking University is one of the five colleges & universitys embracing the mostly-time-honored history and disciplinary strength. In the meantime, Peking University is a top-tier university belonging to the projects of 211 & 985, also nominated as one of the two state key educational bodies. Furthermore, the School of Pharmaceutical Sciences, Health Science Center, and other relevant departments & schools are entitled to cutting-edge experimental research platforms and conditions
3. Domestic first-class research team: the laboratory is the first and so far the only innovative team of the Ministry of Education in the field of Pharmaceutics in China; Professor Qiang Zhang, director of the laboratory, has served as the chairman of the Pharmaceutics Professional Committee of the Chinese Pharmaceutical Association for a long time and is the first chairman of the China Branch of World Controlled Release Association (CRS); our team members include 973 Chief Scientist, Outstanding Young Scholars of the National Foundation Commission, Yangtze River Scholars, Scholars of Thousand Youth Talents Program, Excellent Young Scholars of the National Foundation Commission and Outstanding Young Scholars of Beijing, etc. Besides, two of them have been chosen as the Elsevier Highly Cited Authors in China.

Important Scientific Achievements and Contributions in Recent Years

In recent years, in response to major scientific issues in the field of Molecular Pharmaceutics, the laboratory has originally constructed a selective nanocarriers avoiding lysosomal degradation, an intelligent nano-diagnosis and treatment system that responds to molecular signals inside and outside cancer cells with precise procedures, and the co-delivery system based on nano covalent organic polymer, etc., realizing efficient and specific drug delivery; took the lead in applying proteomics technology to reveal the new molecular mechanism of molecular microenvironment regulating the cellular transport pathway of the nanocarriers, and discovered that the anisotropy of ligands regulates nano-biological interaction for the first time, clarifying a series of key scientific issues at the molecular level. In terms of new drug delivery systems, various high-end pharmaceutical preparations have been technologically transformed by our laboratory in recent years. Moreover, our team has published a series of highly influential academic papers in academic journals such as the journals of Nature Press; widely developed cooperation with large domestic and foreign pharmaceutical companies; organized and participated in a number of large-scale academic activities at home and abroad, and obtained the National Science and Technology Progress Award, the Natural Science Award of the Ministry of Education and Beijing Science and Technology Award.

 

Director: Qiang Zhang

Contact: Hua Zhang

Email: zhangpharm@bjmu.edu.cn

TEL: 010-82805724

Address: No. 38 Xueyuan Road, Haidian District, Beijing